Dario's leading behavior change solutions continue to win interest in the employer, payer and pharmaceutical markets NEW YORK, July 16, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO)...
|
New research confirms behavior change driven by Dario digital platform is sustainable for 12 month period and supports clinical results for members taking a GLP-1 Additional research demonstrates...
|
After two decades of successfully scaling multiple healthcare companies, Steven Nelson joins DarioHealth as Chief Commercial Officer to accelerate revenue growth across the health plans, employers...
|
First quarter revenue of $5.8 million reflects an increase of 59% over fourth quarter of 2023 primarily resulting from an increase in B2B2C revenues and reflects a decrease of 18.5% compared to...
|
DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today that it will release its financial results for the 1st quarter ended March 31st, 2024,...
|
Quasi-randomized study demonstrates the value of Dario's integrated approach to provide one solution for members to manage diabetes, pre-diabetes, blood pressure, weight and taking a GLP-1 NEW...
|
Dario selected to provide integrated and proven solutions to improve employee cardiometabolic health NEW YORK, April 18, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"
|
Studies include a Randomized Controlled Trial demonstrating significant reduction in perceived stress for teens NEW YORK, April 10, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario"...
|
Dario selected to provide integrated approach to improve employee cardiometabolic health - including support for those taking a GLP-1 medication - musculoskeletal and behavioral health NEW YORK,...
|
Full-year 2023 revenue of $20.4 million reflects a decrease from 2022 revenue of $7.3 due to a managed decrease in B2C and strategic milestone revenue as the core B2B2C revenue increased. 2023...
|
DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today that it will release its financial results for the 4th quarter ended December 31, 2023,...
|
Study presented at ATTD 2024 is the first of a planned series examining the impact of Dario's integrated cardiometabolic solution as a means to address weight and diabetes with or without a GLP-1...
|
DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital health market, today announced that management will participate in the Cowen 44th Annual Healthcare Conference, which is being held...
|
Expecting nearly doubling Dario's pro forma revenues in 2023 Acquisition is immediately accretive to revenue and gross margins and expected to accelerate path to profitability Concurrent with the...
|
Dario's integrated solution to support improved whole health gains traction in public and labor market NEW YORK, Jan. 11, 2024 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the...
|
|